Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02180581
Other study ID # H-4-2014-032
Secondary ID H-4-2014-032
Status Completed
Phase N/A
First received June 30, 2014
Last updated August 23, 2016
Start date August 2014
Est. completion date June 2016

Study information

Verified date August 2016
Source University of Copenhagen
Contact n/a
Is FDA regulated No
Health authority Denmark: The Regional Committee on Health Research Ethics
Study type Interventional

Clinical Trial Summary

The aim of the intervention is to examine the effect of a combination of the two bacterial strains BB-12 and LGG, provided for 6 month, on the prevalence of infections and allergic manifestations in small children, and how a combination of BB-12 and LGG affects the immune system, gastrointestinal tract and the microbiota. Children are enrolled during 2 winter seasons.


Recruitment information / eligibility

Status Completed
Enrollment 290
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 8 Months to 14 Months
Eligibility Inclusion Criteria:

- Expected to start daycare between the age of 8-14 month

- Intervention start 0 days to 12 weeks before starting daycare

- Expected to start daycare from september to february (both month included)

- Single born

Exclusion Criteria:

- Exclusion Criteria:

- Children born before 37th gestational week

- Children with a birth weight < 2500 g

- Children suffering from severe chronic illness

- Children receiving regular medication

- Children who have received antibiotics within a month before intervention start

- Children whose parents do not speak Danish

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Dietary Supplement:
Probiotic (2 * 10^9 cfu/day)
Combination of two probiotics (2 * 10^9 cfu/day) or probiotics for 6 months
Placebo
Placebo for 6 months

Locations

Country Name City State
Denmark Section of Paediatric and International Nutrition, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen Frederiksberg

Sponsors (7)

Lead Sponsor Collaborator
University of Copenhagen Chr Hansen A/S, Odense University Hospital, Statens Serum Institut, Technical University of Denmark, The Danish Council for Strategic Research, University of Bergen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline in biological markers for the immune system Analysis of biological material investigating the effect on the immune system by biological markers . At baseline and after 6 mo No
Other Change from baseline in biological markers for gastro-intestinal tract Analysis of biological material investigating the effect on the gastrointestinal tract. At baseline and after 6 mo No
Other Change from baseline in Biological markers of allergy analysis of biological samples investigating the effect on allergy by biological markers at baseline and at 6 mo At baseline and after 6 mo No
Primary Number of days absent from daycare due to respiratory and gastrointestinal infections Recorded weekly by the parents using web-based questionnaires up to 6 month No
Secondary Acute upper respiratory tract infections Number of days with acute upper respiratory tract infections (URTI); Number of children with at least 1 episode of URTI; Number of children with at least 3 episodes of URTI; Number of URTI episodes/child/year; Duration of URTI episodes (days);
Additionally,symptoms of cold (defined as 2 days with runny/stuffy nose or cough)
Recorded by the parents daily/weekly using web-based questionnaires.
Up to 6 month No
Secondary Acute lower respiratory infections Number of children with at least 1 episode of a lower respiratory tract infection (LRTI).
LRTI include bronchitis and pneumonia
Recorded by the parents weekly using web-based questionnaires.
Up to 6 month No
Secondary Gastrointestinal infections Number of children with at least 1 episode of diarrhea; Duration of episodes with diarrhea(days); Number of episodes/child/year with diarrhea; Number of days with vomiting.
Recorded by the parents daily using web-based questionnaires
Up to 6 month No
Secondary Fever Number of days with fever
Recorded by the parents using web-based questionnaires
Up to 6 month No
Secondary Antibiotic use Number of treatments with antibiotics during the intervention period
Recorded weekly by the parents using web-based questionnaires
Up to 6 month No
Secondary Allergies Number of children developing allergies during the intervention period (asthma, allergic rhinitis, atopic dermatitis, food allergies); Age for diagnosis of allergies; Use of medication due to allergies.
Recorded by the parents using web-based questionnaires
Up to 6 month No
Secondary Absence from day care due to illness other than infections Number of days the child is absent from day care due to illness, which is not due to infections.
Recorded by the parents weekly using web-based questionnaires
Up to 6 month No
Secondary Parental absence from work due to illness of the child Number of days a parent is absent from work due to illness of the child (infections and other illnesses, respectively)
Recorded by the parents weekly using web-based questionnaires
Up to 6 month No
Secondary Medical visits Number of visits to a doctor due to infections and other illnesses, respectively.
Recorded by the parents using web-based questionnaires
Up to 6 month No
Secondary Change from baseline in Thymus size Change in thymic size during intervention period will be evaluated using ultrasound At baseline and after 6 mo (end of intervention) No
See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT02306473 - The Leaky Lung Test Early Phase 1
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3